» Articles » PMID: 6693039

Selective and Non-selective Beta Receptor Blockade in the Reduction of Portal Pressure in Patients with Cirrhosis and Portal Hypertension

Overview
Journal Gut
Specialty Gastroenterology
Date 1984 Feb 1
PMID 6693039
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

To elucidate the mechanisms by which beta receptor blockade leads to a reduction of portal pressure, 18 patients with cirrhosis and portal hypertension were given comparable doses of propranolol or metoprolol. The fall in portal pressure was more marked with propranolol together with a significant reduction in hepatic blood flow, which was not seen with metoprolol. No correlation between the reduction in cardiac output and the decrease in portal pressure or changes in hepatic blood flow could be elicited in each group, but there was a direct relationship between the decrease in hepatic blood flow and fall in portal pressure in the propranolol treated patients. The difference observed may be related to blockade of beta 2 vasodilator receptors in the splanchnic circulation which will occur only with propranolol and lead to a greater fall in splanchnic blood flow than will be produced by a reduction in cardiac output alone. Metoprolol, by maintaining effective hepatic blood flow, may be preferable to propranolol in patients with severely impaired liver function.

Citing Articles

Close Relationship between Systemic Arterial and Portal Venous Pressure in an Animal Model with Healthy Liver.

Lazaro A, Stoll P, von Elverfeldt D, Kreisel W, Deibert P Int J Mol Sci. 2023; 24(12).

PMID: 37373109 PMC: 10298130. DOI: 10.3390/ijms24129963.


Nonselective beta-blockers and development of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis.

Xu X, Guo X, De Stefano V, Silva-Junior G, Goyal H, Bai Z Hepatol Int. 2019; 13(4):468-481.

PMID: 31175581 DOI: 10.1007/s12072-019-09951-6.


Decreased portal vein velocity is predictive of the development of portal vein thrombosis: A matched case-control study.

Stine J, Wang J, Shah P, Argo C, Intagliata N, Uflacker A Liver Int. 2017; 38(1):94-101.

PMID: 28632958 PMC: 10540634. DOI: 10.1111/liv.13500.


β-Blocker therapy ameliorates hypersplenism due to portal hypertension in children.

Poddar U, Shava U, Yachha S, Agarwal J, Kumar S, Baijal S Hepatol Int. 2015; 9(3):447-53.

PMID: 25788181 DOI: 10.1007/s12072-014-9575-z.


Primary prophylaxis of variceal hemorrhage in children with portal hypertension: a framework for future research.

Ling S, Walters T, McKiernan P, Schwarz K, Garcia-Tsao G, Shneider B J Pediatr Gastroenterol Nutr. 2011; 52(3):254-61.

PMID: 21336158 PMC: 3728696. DOI: 10.1097/MPG.0b013e318205993a.


References
1.
Price H, COOPERMAN L, Warden J . Control of the splanchnic circulation in man. Role of beta-adrenergic receptors. Circ Res. 1967; 21(3):333-40. DOI: 10.1161/01.res.21.3.333. View

2.
Forrester J, Ganz W, Diamond G, McHugh T, Chonette D, Swan H . Thermodilution cardiac output determination with a single flow-directed catheter. Am Heart J. 1972; 83(3):306-11. DOI: 10.1016/0002-8703(72)90429-2. View

3.
Pugh R, Murray-Lyon I, Dawson J, Pietroni M, Williams R . Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973; 60(8):646-9. DOI: 10.1002/bjs.1800600817. View

4.
Caesar J, Shaldon S, Chiandussi L, Guevara L, Sherlock S . The use of indocyanine green in the measurement of hepatic blood flow and as a test of hepatic function. Clin Sci. 1961; 21:43-57. View

5.
Richardson P, Withrington P . Liver blood flow. II. Effects of drugs and hormones on liver blood flow. Gastroenterology. 1981; 81(2):356-75. View